Codexis Inc (CDXS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Codexis Inc (CDXS) has a cash flow conversion efficiency ratio of -0.200x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.70 Million) by net assets ($38.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Codexis Inc to measure how much of total assets are equity-financed.
Codexis Inc - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Codexis Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check CDXS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Codexis Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Codexis Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Deleum Bhd
KLSE:5132
|
0.209x |
|
It's Skin Co Ltd
KO:226320
|
0.019x |
|
51Talk Online Education Group
NYSE MKT:COE
|
-0.378x |
|
Unique Optical Industrial Co Ltd
TWO:3441
|
0.072x |
|
PYRUM INNOV.AG NA O.N.
F:PYR
|
-0.116x |
|
Keyrus SA
PA:ALKEY
|
-0.164x |
|
Maxigen Biotech Inc
TW:1783
|
0.049x |
|
Khonburi Sugar Public Company Limited
BK:KBS
|
0.252x |
Annual Cash Flow Conversion Efficiency for Codexis Inc (2006–2024)
The table below shows the annual cash flow conversion efficiency of Codexis Inc from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Codexis Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $66.93 Million | $-49.41 Million | -0.738x | -21.48% |
| 2023-12-31 | $86.61 Million | $-52.64 Million | -0.608x | -879.84% |
| 2022-12-31 | $144.80 Million | $11.28 Million | 0.078x | +189.79% |
| 2021-12-31 | $164.39 Million | $-14.27 Million | -0.087x | +10.33% |
| 2020-12-31 | $170.10 Million | $-16.46 Million | -0.097x | +18.69% |
| 2019-12-31 | $105.52 Million | $-12.56 Million | -0.119x | +52.45% |
| 2018-12-31 | $56.31 Million | $-14.09 Million | -0.250x | +29.88% |
| 2017-12-31 | $24.55 Million | $-8.76 Million | -0.357x | -152.43% |
| 2016-12-31 | $19.10 Million | $-2.70 Million | -0.141x | -647.25% |
| 2015-12-31 | $22.88 Million | $-433.00K | -0.019x | -255.13% |
| 2014-12-31 | $26.31 Million | $321.00K | 0.012x | +102.20% |
| 2013-12-31 | $41.48 Million | $-23.00 Million | -0.554x | -265.68% |
| 2012-12-31 | $78.44 Million | $-11.89 Million | -0.152x | -3077.24% |
| 2011-12-31 | $102.69 Million | $-490.00K | -0.005x | +96.87% |
| 2010-12-31 | $107.36 Million | $-16.38 Million | -0.153x | +35.29% |
| 2009-12-31 | $36.84 Million | $-8.69 Million | -0.236x | -183.84% |
| 2008-12-31 | $-129.12 Million | $-36.32 Million | 0.281x | +280.22% |
| 2007-12-31 | $-87.47 Million | $-6.47 Million | 0.074x | -70.62% |
| 2006-12-31 | $-52.77 Million | $-13.29 Million | 0.252x | -- |
About Codexis Inc
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the … Read more